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Abstract
Background: Mycobacterium tuberculosis infects nearly 1/3 of the world population and this reservoir forms the largest pool
from which new cases arise. Among the cytokines, IFN-c is a key determinant in protection against tuberculosis. Single
nucleotide polymorphisms (SNPs) in IFN-c gene (+874 T/A) which determine TT high (hi), AA low (lo) and TA intermediate (int)
responder phenotypes have shown variable associations with tuberculosis disease outcome in different ethnic populations.
The objective of the current study was to analyze IFN-c gene combinations with other IFN-c regulating cytokine genes (IL-
10, TNF –a, IL-6) to see the effect of gene- combinations on disease severity outcome in pulmonary tuberculosis.
Methods and Findings: Study groups comprised of pulmonary TB patients stratified according to lung tissue involvement
into mild (Pmd=74) or advance (Pad = 23) lung disease and compared with healthy controls (TBNA= 166). Genotype
analysis was carried out using amplification refractory mutation system-PCR (ARMS-PCR). IFN-c gene (+874 T/A) functional
SNP combinations in TNFa (2308 G/A), IL-10 (21082 A/G) and IL-6 (2174 G/C) were analyzed. Single gene analysis (Pearson
x2) showed a dominant association of IFN-c TT hi genotype (p = 0.001) and T allele (p = 0.001) with mild disease. IFN-clo -IL-
10lo genotype combination was associated with advanced disease (p = 0.002). IFN-chi –IL-6 hi combination was associated
with mild disease (p = 0.0005) while IFN-clo –IL-6 int was associated with protection against both forms of pulmonary disease
(p = 0.002).
Conclusion: Our results show that a limited number of IFN-c gene combinations with other cytokine functional SNPs
determine the outcome of disease severity in tuberculosis.
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Introduction
Despite dramatic declines in industrialized countries, there are
over 8 million new cases of M. tuberculosis (MTB) every year, 1.5
million deaths, and 40 million new infections [1]. Among the 20
high TB burden countries, Pakistan ranks 8th despite .95%
coverage with BCG vaccination at birth [2]. Of those exposed to
tuberculosis, only about 30% are thought to develop the state of
latent infection, during which the host remains clinically well, but
bacilli survive within granulomae in a dormant state. Therefore,
the normal human immune system is substantially equipped to
control a TB infection [3]. Of those harboring a latent infection,
on average, only 5–10% will progress to active clinical disease,
approximatelyK within the first 2–3 years following infection [4].
There is a large body of evidence that genetic factors may play an
important role in determining susceptibility as well extent of
disease severity in TB.
Cytokines play an important role in orchestrating the immune
response which is activated as a network of pro-inflammatory and
down-regulatory cytokines derived from both T cells and
macrophages and determine the disease outcome in TB.
Interferon (IFN)-c derived from activated Th1 cells plays a pivotal
role in mycobacterial immunity [5–6]. However, IFN-c gene (+874
T/A) single nucleotide polymorphisms (SNPs) which is related to
the high (hi), intermediate (int) and low (lo) responder phenotype has
shown variable effects in different populations [7]. Cytokines that
affect the functionality of IFN-c render the host susceptible to
severe disseminated disease [8–12]. Among the pro inflammatory
cytokines, Tumor Necrosis Factor-Alpha (TNF-a) in conjunction
with IFN- c plays a key role in the initiation, regulation, and
maintenance of the inflammatory response generated by MTB. In
autoimmune conditions and HIV patients, treatment with drugs
aimed at blocking TNF-a have shown activation of latent TB [13].
TNF-a 2308 G/A SNP, a functional polymorphism, has shown
association with severe forms of malaria [14], leishmaniasis [15],
and leprosy [16], in conjunction with raised levels of TNF-a in
peripheral blood, but this SNP has shown no association with
either disease susceptibility [17–18], [19], or severity in TB [20].
The effects of pro-inflammatory cytokines are counterbalanced by
down-regulatory cytokines such as interleukin-10 (IL-10) which is
produced by the activated macrophages, monocytes, Th2 [21],
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and T regs [22], in response to infection. The IL-10 21082 G
SNP correlates with high responder phenotype after in vitro
stimulation of T cells [23]. High levels of IL-10 may prevent
collateral tissue damage particularly in the lung [22] during the
chronic phase of pulmonary TB but may lead to disease activation
during the early or latent phase of infection by down regulating
both TNF-a and IFN-c [24]. Data on association of 21082 G/A
SNP and TB is also highly variable [25].
A biallelic polymorphism has also been identified at position
2174 (G/C) in the promoter region with the allele G found to be
associated with higher IL-6 production [26]. To date no
association has so far been reported with IL-6 2174 SNP and
TB [20], [27], although IL-6 is recently being recognized as part of
the Th2 loop [28], which down regulates Th1 responses. We have
also recently reported that endogenously activated high levels of
IL-6 in conjunction with high levels of IL-4 was associated with
disease progression in recently exposed household contacts of TB
patients [29].
Because of the complexity of immune interactions which
determine TB disease susceptibility and severity, multi-gene
combination may give more meaningful insights than single SNP
analysis in determining disease outcome [30–31]. Since IFN-c is a
key player in immunity to mycobacterial diseases we have
investigated the combination of SNP +874 (T/A) with functional
SNPs in other cytokines genes (IL-10, TNF-a and IL-6) to see if
some of the variability in single gene association studies in different
ethnic populations could be explained by multi-gene combination.
Our results show that a few selected combinations of IFN-c
cytokine gene with other cytokine genes SNPs determine the
outcome of disease severity in TB.
Materials and Methods
Study Groups
The patient population was drawn from a hyper-endemic area
in Karachi (Kharadar). Healthy controls consisted of TB not
affected (TBNA=166) donors, drawn from within the community
(HC=78) and outside the community (EC=88) and who had no
co-morbids conditions, signs, symptoms or history of previous TB.
Inclusion criteria. The TB patient group comprised of
pulmonary TB (PTB=102) with involvement of lung parenchyma
only. Exclusion criteria: Patients with immunosuppressive
condition such as HIV, diabetes or on steroids for inflammatory
conditions were excluded from the study. Diagnosis of PTB was
confirmed by microscopy for presence of acid fast bacilli or
sputum culture positivity (N= 55), radiology (N= 42) or clinical
response to treatment (N=5). PTB patients where radiological
lung tissue involvement (N= 97) was available were further
stratified into minimal (n = 10)/moderate (N= 64) or advanced
(P ad= 23) disease according to non-HIV related TB guidelines for
disease classification [32–33]. Five TB patients had been treated
for PTB but radiological classification for disease severity was not
available and therefore, excluded from the disease severity studies.
IFN-c -874 SNP showed similar frequencies in PTB patients
with minimal and moderate lung involvement and were grouped
as mild disease (P md= 74) for analysis of cytokine gene
polymorphisms. This study was approved by The Aga Khan
University Ethical Review Committee (1452-PATH-ERC). Writ-
ten consent was obtained from each participant.
Tuberculin skin tests
Tuberculin skin test (TST) positivity was assessed by adminis-
tering 5 tuberculin units intra-cutaneously on the volar surface of
the right arm [34]. An induration of $10 mm after 48 hours was
considered positive (TST+).
Molecular Template Preparation
Two to five ml of blood was collected from all donors in ACD
tubes (VWR Scientific, West Chester, PA, USA) and kept frozen at
235uC. Human genomic DNA was extracted from frozen whole
blood at room temperature (25uC) after thawing and proper
mixing of the tubes using Promega Wizard Genomic DNA
Purification Kit (Promega Corporation Madison, WI, USA)
according to the manufacturer’s instructions. Extracted DNA
was run on 0.8% agarose gel to check the quality of the DNA.
Spectrophotometery was also done to check the concentration and
purity of the DNA and stored at 4uC until further use.
Molecular Methods
Primers were purchased from MWG-Biotech AG (Ebersberg,
Germany). The sequences are given in Table S1. IFN-c
(rs2430561), IL-10 (rs1800896) and TNF-a (rs1800629) genotyping
were carried out using amplification refractory mutation system-
PCR (ARMS-PCR) with human growth hormone (HuGH) or b-
actin primers as internal controls to check the accuracy of PCR
reactions. IL-6 (rs1800795) genotyping was carried out using tetra-
ARMS PCR. Amplified products (5 ml undiluted) were monitored
by electrophoresis on agarose gel prepared in Tris-acetate EDTA
(TAE) buffer containing 10 mg/ml ethidium bromide. Product
bands were visualized on a UV-transilluminator and pictures were
taken for the interpretation of genotypes.
Confirmatory Sequencing Methodology
Sequencing methodology was used on a subset of samples (10–
15% for each SNP) to confirm genotypes identified by ARMS and
tetra-ARMS PCRs. The primers for sequencing reactions of IFN-c
and IL-10 were designed using software Lasergene version 7.0
(DNAstar, Madison, WI, USA) while primers for TNF-a and IL-6
were designed using web based software ‘‘BatchPrimer3’’ (Table
S1). Amplified PCR products (25–30 ul) were sent to Macrogen
(Macrogen Inc, Seoul, Korea) for sequencing. Sequencing results
were analyzed by pair-wise alignments of the sequences using
software ‘‘ClustalW version 1.83’’. The allelic specificities of the
cytokine gene SNPs were determined by a comparison of PCR
results with nucleotide sequencing results of the alleles. Greater
than 95% concordance was observed in all cases.
Statistical Analysis
Epi- Info (version 6) was used to estimate the sample size with
95% confidence interval and 80% power of the study. We have
used genotype frequencies in the Iranian population [35], for
sample size calculations and added ,20–25% for variability in
frequency. Statistical Package for Social Sciences (SPSS version
19.0 IBM Corporation, NY, USA) was used. Groups were
compared for differences in allele and genotypes frequencies by
Pearson Chi squared or Fisher’s exact tests, when the criteria for
the chi-squared analysis were not fulfilled. P values of #0.05 were
considered significant for both Pearson and Fisher’s exact tests.
For significant p-values, odds ratios (OR) with respective
confidence intervals (95% CI) were also calculated. Odds Ratio
(OR) was not available for all values because at least for one case,
the value of the weight variable was zero. Linear-by-linear test
were used to determine the corrected p-values for comparisons
between groups and Bonferroni correction was applied when
multiple comparisons were carried out. Multiple logistic regression
analysis was applied to determine the effect of age and sex with
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genotypes. Hardy-Weinberg Equilibrium (HWE) was determined
by applying the equation (p2+2pq+q2). IFN-c +874 T/A genotype
combinations with IL-10 21082 A/G, TNF-a -308G/A and IL-6
2174 G/C were used to determine two gene combination effect.
Nine possible genotype combinations were derived with IFN-c
genotypes for each of the cytokine genotypes. These combinations
were then compared between controls and PTB patients using
Pearson x2 or Fisher’s exact test.
Results
The patients population was drawn from a hyperendemic area
in Karachi (Kharadar) described in detail previously [34]. The age
and gender distribution of donor groups included in the study are
given in Table 1. There was no significant difference in these
parameters between control and patient groups (x square test).
The rate of TST+ (.=10 mm indurations) was 83% in PTB
patients and 61% in healthy donors (TBNA). The high rate of
TST+ in healthy control is not surprising as the setting of this
study is in a high transmission pocket in Karachi [36]. Single
nucleotide polymorphisms (SNPs) in IFN-c gene (+874 T/A) which
determine TT high (hi), AA low (lo) and TA intermediate (int)
responder phenotypes were analyzed in relation to disease
susceptibility and severity in pulmonary tuberculosis.
Cytokine SNP Genotypes and Allele frequencies in
pulmonary tuberculosis patients
ARMS-PCR is a simple and reliable method for SNPs analyses
as this methodology does not require restriction enzyme digestion
or allele specific oligonucleotides and thus reduces sample
handling. A concordance of .95% was observed between
ARMS-PCR and sequencing (N=40) (data not shown). To
control for the population differences we tested healthy controls
from within the community (HC=78) and outside the community
(EC=88) and saw no differences in frequencies (IFN-c, p = 0.590;
IL-10, p = 0.296; TNF-a, p = 0.535; IL-6, p= 0.662). We therefore
pooled the two control groups (TBNA=166) for comparison with
the tuberculosis patients. All genotypes were in Hardy-Weinburg -
Equilibrium. Table 2 shows the distribution of genotype and allele
for all four cytokines. We used additive and multiplicative models
for analyses of association of genotypes and alleles with pulmonary
TB and disease severity in pulmonary TB (Table 2).
IFN-c (+874 T/A) SNP shows significant association with
pulmonary disease
A significant association of TThi genotype (p = 0.019; TST+
corrected p= 0.024) as well as the T allele (p = 0.018, TST+
corrected p= 0.023) was observed with PTB. This association was
Table 1. Demographic Characteristics of TB affected and TB
not affected donors.
Group N Age (mean) SD ±1
Gender M:F
(ratio) % TST+
TBNA 166 28.3 12.1 83/83 (1) 61
PTB 102 31.8 16.5 44/58 (0.76) 83
a) Pmd 74 32.4 15.9 33/41 (0.8)
b) Pad 23 27 17 9/14 (0.64)
Note: TBNA=TB not affected; PTB = Pulmonary tuberculosis; Pmd= Pulmonary
patients with min/mod lung involvement; Pad = Pulmonary patients with
extensive lung involvement.
TST+= Tuberculin Skin Test$10 mm induration.
doi:10.1371/journal.pone.0027848.t001
Table 2. Cytokine gene polymorphisms in Pakistani
Pulmonary Tuberculosis Patients.
Cytokines SNP
TBNA
(166) PTB (102) Pmd (74) Pad(23)
n % n % n % N %
IFN-c GN TT 21 12.65 24 23.53 22 29.73 2 8.7
(+874 T/A) TA 80 48.19 48 47.06 34 45.95 11 47.83
AA 65 39.16 30 29.41 18 24.32 10 43.48
x2 5.49 10.44 0.31
p = 0.019 0.001 0.577
IFNc Allele T 122 36.75 96 47.06 78 52.7 15 32.61
(+874 T/A) A 210 63.25 108 52.94 70 47.3 31 67.39
x2 5.56 10.7 0.3
p = 0.018 0.001 0.584
OR 1.53 1.92 0.83
95% CI 1.07–2.18 1.30–2.84 0.43–1.60
IL-10 GN AA 31 18.67 23 22.55 17 22.97 6 26.09
(21082 A/G) AG 118 71.08 64 62.75 48 64.86 11 47.83
GG 17 10.24 15 14.71 9 12.16 6 26.09
x2 0.01 0.1 0.46
p = 0.933 0.757 0.498
IL10 Allele A 152 45.78 94 46.08 66 44.59 23 50
(21082 A/G) G 180 54.22 110 53.92 82 55.41 23 50
x2 0 0.06 0.29
p = 0.947 0.809 0.591
OR 1 1.05 0.85
95% CI 0.69–1.4 0.71–1.55 0.46–1.57
TNFa GN GG 83 50 51 50 41 55.41 8 34.78
(2308 G/A) GA 83 50 51 50 33 44.59 15 65.22
AA 0 0 0 0 0 0 0 0
x2 0 0.6 1.86
p = 1 0.44 0.172
TNFa allele G 249 75 153 75 115 77.7 31 67.39
(2308 G/A) A 83 25 51 25 33 22.3 15 32.61
x2 0 0.41 1.22
p = 1 0.523 0.27
OR 1 0.86 1.45
95% CI 0.70–1.50 0.54–1.36 0.75–2.82
IL-6 GN GG 100 60.24 74 72.55 51 68.92 18 78.26
(2174 G/C) GC 56 33.73 24 23.53 19 25.68 5 21.74
CC 10 6.02 4 3.92 4 5.41 0 0
x2 3.79 1.22 3.31
p = (0.052) 0.27 0.069
IL-6 allele G 256 77.11 172 84.31 121 81.76 41 89.13
C 76 22.89 32 15.69 27 18.24 5 10.87
x2 4.07 1.31 3.47
p = 0.044 0.252 0.063
OR 0.63 0.75 0.41
95% CI 0.40–0.99 0.46–1.23 0.16–1.08
Note: Abbreviations for groups are as described in table 1. Group N is given in
brackets. Groups were compared with TBNA. Pearson x2 or Fisher exact test
was performed to determine group differences. Linear by linear corrected p
values are shown. Significant differences (p,0.05) are in bold. Association with
protection is given in italics.
doi:10.1371/journal.pone.0027848.t002
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restricted to P md (TT genotype p= 0.001, TST corrected
p= 0.002; and T allele, p = 0.002) suggesting that the presence of
this genotype increases the risk of P md (OR 1.92; CI = 1.07–2.84)
(Table 2). As previously reported [37], no association was found
with Pad (p= 0.591). T allele therefore shows association with the
less severe form of pulmonary TB (Table 2).
IL-10 (21082 A/G), TNF-a (2308 G/A) SNPs
IL-10 (21082A/G) and TNF-a (2308G/A) genotype and allele
frequencies showed no significant differences between disease and
control subjects in relation to either site (PTB) or severity of
pulmonary disease (Table 2). Correction for TST+ controls gave
similar results (Table 2).
IL-6 (2174G/C)
The genotype frequency of IL-6 (2174G/C) indicated a trend
(p = 0.052) with lower frequency of CC in the PTB group but was
not significant when corrected for TST+ (p = 0.179). This trend
achieved statistical significance (p= 0.044) when alleles were
compared, with the C allele showing lower frequency in PTB
patients and decreased the risk of PTB disease (OR=0.63;
CI = 0.40–0.99) compared to healthy controls. However this trend
again was not significant when corrected for TST+ (p = 0.147).
In addition to the multiplicative and additive models, we also
analyzed the dose effect of genotypes using the dominant and
recessive model for each of the 4 genotypes (Table 3). The effect of
IFN- c +874 T allele was a dominant trait while the IL-10 A allele
showed a recessive trait. TNF-a and IL-6 were not significant in
this model (Table 3).
IFN- c +874 T/A gene combination with IL-10, TNF-a, IL-6
on PTB disease severity
Deficiencies in IFN- c and cytokines regulating or modulating
the IFN- c response have been shown to have profound effect on
mycobacterial immunity and in some cases has resulted in
Mendelian Susceptibility to Mycobacterial Diseases (MSMD)
[38]. We therefore analyzed the effect of IFN- c +874 SNPs in
combination with other promoter region SNPs in cytokines IL-10,
TNF-a, IL-6 (Table 4). For each cytokine, nine combinations were
generated with IFN- c +874 T/A SNPs. The frequency (%) and
number (n) is given for all groups but statistics for only significant
values are shown (Table 4). Uncorrected p values,0.005 were
considered significant as there were 9 possible combinations
(Bonferroni correction).
1. Combinations of IFN- c +874 T/A with IL-10 -1082
A/G SNPs. Although IL-10 -1082 A/G SNP showed no
association with pulmonary TB (Table 2) when analyzed singly
but had an effect in combination with IFN- c +874 T/A SNP
(Table 4). Absence of IFN- c +874 hi IL-10 int, resulted in
increased risk of Pad (p= 0.002). In addition presence of IFN- c
+874 lo IL-10 lo also increased the risk of Pad (p= 0.0022,
OR=3.59, CI = 1.12–11.41) (Table 4). These results were
statistically significant even when strict bonferroni correction
was applied. IFN-c is a potent pro-inflammatory cytokine.
Therefore, high IFN-c levels have to be counterbalanced with
down regulatory IL-10 to reduce collateral damage. These
results are therefore in line with the biological functions of IFN-
c and IL-10. No association was observed with P md for any of
the IFN- c-IL-10 genotype combinations (Table 4).
2. Combinations of IFN- c +874-T/A with TNFa 2308
G/A SNPs. TNF-a, a pro inflammatory cytokine in
conjunction with IFN- c has been shown to play an important
role in granuloma formation and disease localization [39].
When gene combinations for these two cytokines were
analyzed (Table 4), it was interesting to note that weak
associations were noted for IFN- c hi – TNF-a int which
restricted the disease to Pmd (p= 0.018, OR=3.35, CI 1.17–
9.62) while a decreased frequency of IFN- clo – TNF-a int was
Table 3. Effect of cytokine gene dose on severity of pulmonary tuberculosis.
Cytokines SNP Position Genotypes PTB (102) PMN+PMD (74) PAD (23)
P-values P-values P-values
IFNc (+874) TRA Additive 0.046 0.003
Dominant 0.026
Recessive 0.021 0.001
Multiplicative 0.018 0.001
IL-10 (21082) GRA Additive 0.041
Dominant 0.03
Recessive
Multiplicative
TNFa (2308) ARG Additive
Dominant
Recessive
Multiplicative
IL-6 (2174) GRC Additive
Dominant
Recessive 0.041
Multiplicative 0.043
Note: Abbreviations for groups are as described in table 1. Group N is given in brackets.
Groups were compared with TBNA. Pearson x2 or Fisher exact test was performed to determine group differences. Linear by linear corrected p values are shown.
doi:10.1371/journal.pone.0027848.t003
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weakly associated with protection in Pmd (p = 0.036, OR=0.4,
CI = 0.16–0.96) (Table 4) suggesting that IFN- c hi may be
responsible for tissue damage in Pmd. This is further supported
by the observation that lack of IFN- c hi – TNF-a lo increases
the risk of Pad (p = 0.01) which is again in line with the role of
these two cytokines. Although these associations are weak and
become insignificant when strict bonferroni correction was
applied, these results to some extent may explain the
controversial association of IFN- c lo and IFN- c hi alleles with
either susceptibility or protection for PTB in different ethnic
population which may be related to the differential frequencies
of IFN-c SNPs [7], in relation to other cytokine gene SNPs.
3. Combination of IFN- c +874-T/A with IL-6 2174 G/C
SNPs. IL-6 is part of the acute phase responses but its
biological functions are just being defined in the activation of
the Th2 network [28]. Single polymorphisms with IL-6 2174
SNPs in different studies have shown no association with PTB
[27], [20]. It was therefore interesting to note clear cut
associations with disease protection and susceptibility when the
combinations of this cytokine with IFN- c were analyzed. There
was one combination, IFN-clo -IL-6 int which was decreased
across the pulmonary disease spectrum and was associated with
decreased risk of pulmonary TB (Table 4). This combination
(IFN-clo IL-6 int) also showed greater protection with moderate
disease (Pmd ; p= 0.005; OR=0.06) compared to advanced
disease (Pad; p = 0.013, OR=0.26). Increased frequency in
IFN- c hi - IL-6 hi was associated with increased risk of Pmd
(p = 0.0005; OR=6.0, CI = 1.97–18.27) but not Pad (Table 4).
Tables 4. IFN -c Genotype combination: frequency and association with tuberculosis disease susceptibility and severity.
IFNc-IL10
TBNA %
(n=166)
PTB%
(n=102) p-value; x2 OR (95% CI)
Pmd %
(n=74 ) P-value; x2 OR (95% CI)
P ad %
(n=23) *P-value; x2 OR (95% CI)
TTHigh-AAHigh 6.42 8.82 4.48 4.35
TTHigh-AGInt 8.56 10.78 5.97 0.00 0.002; 29.42
TTHigh-GGLow 3.21 5.92 2.99 4.35
TAInt-AAHigh 5.88 7.84 2.99 8.7
TAInt-GAInt 38.5 34.31 43.28 30.43
TAInt-GGLow 3.74 4.9 2.99 8.7
AALow-AAHigh 5.88 5.88 5.97 13.04
AALow-GAInt 24.06 17.65 29.85 17.39
AALow-GGLow 3.74 5.88 1.49 13.04 0.0022; 5.21 3.59 (1.12–
11.41)
IFNc-TNFa
TTHigh-AAHigh 0.00 0.00 0.00 0.00
TTHigh-GAInt 5.42 12.75 0.048;3.92 2.84 (0.97–8.29) 14.86 0.018; 5.56 3.35 (1.17–
9.62)
8.7
TTHigh-GGLow 7.23 10.78 14.86 0 0.01; 27.25
TAInt-AAHigh 0.00 0.00 0.00 0.00
TAInt-GAInt 26.51 24.51 21.62 30.43
TAInt-GGLow 21.69 22.5 24.32 17.39
AALow-AAHigh 0.00 0.00 0.00 0.00
AALow-GAInt 18.07 12.75 8.11 0.036; 4.42 0.4 (0.16–0.96) 26.09
AALow-GGLow 21.08 16.67 16.22 17.39
IFNc-IL6
TThigh-GGhigh 4.22 15.69 0.005;8.00 4.57 (1.47–14.21) 20.27 0.0005;
12.12
6.0 (1.97–
18.27)
4.35
TThigh-GCInt 7.83 6.86 8.11 4.35
TThigh-CClow 0.60 0.98 1.35 0.00
TAInt-GGHigh 32.53 30.39 27.03 34.78
TAInt-GCInt 11.45 14.71 16.22 13.04
TAInt-CClow 4.22 1.96 2.70 0.00
AAlow-GGHigh 23.49 26.47 21.62 39.13 0.014; 25.98 2.14 (1.16–
3.96)
AALow-GCInt 14.46 1.96 0.002;9.78 0.13 (0.03–0.57) 1.35 0.0005;
12.18
0.06 (0.01–
0.48)
4.35 0.013; 6.1 0.26 (0.08–
0.81)
AALow-CCLow 1.2 0.98 1.35 0.00
Note: Abbreviations same as in table 1. Number in columns indicates the frequency as percent of total in each group given in brackets.
*Uncorrected p values.
P,0.005 (underlined) was considered significant after Bonferroni correction for multiple comparisons. Values in italics indicate protection and in bold indicate
susceptibility.
doi:10.1371/journal.pone.0027848.t004
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In summary there were only a limited set of combinations with
IFN-c which showed significant association with either
susceptibility or severity of pulmonary disease. Interestingly
different gene combinations were associated with the less severe
(IL-6; Pmd) or more severe form (IL-10; Pad) of pulmonary
disease.
Discussion
Single nucleotide functional polymorphisms in cytokine genes
have shown variable associations with TB site and severity of disease
in different populations and even within the same study population
[7]. Most studies have not differentiated TB disease by site or
severity and therefore it is difficult to evaluate the differences in
results. The strength of our study groups was that we have focused
on a single site (lung) and also stratified the disease severity in this
site. In addition we have analyzed gene combinations with IFN-c
gene which plays a key role in TB disease susceptibility and severity.
Combinations of cytokines SNPs with IFN-c +874 T/A SNP exert
considerable influence on outcome of severity in TB. Our results
may be reflecting polygenic aspects of predisposition to disease
severity and active disease. [40], [31], [38].
The functional SNP at position +874 (T/A) is located at the 59-
end of a CA repeat at the first intron of human IFN-c gene. The T
allele correlates with high IFN-c expression. Transcriptional factor,
NF-kB binds preferably to DNA containing IFN-c +874 T allele,
and increases the expression IFN-c gene. IFN-c +874 single gene
association studies have shown variable results in different ethnic
populations with AA phenotype associated with pulmonary disease
in several studies [41], [23], [12], [42–45]. Interestingly, in two
studies T allele (High producer allele) was associated with either
localized pleural TB disease [20], or with less severe form of the
pulmonary TB but not with advanced pulmonary disease [37].
These differences in observations may be due to the heterogeneity
in SNPs frequencies in different populations [35], and in particular
differences in frequencies of IFN-c +874 TT genotype which varies
from nil to 40 percent (see Table S2).
When we carried out combination analysis in the stratified
groups, only 1/27 possible combinations showed any significant
association with protection across the pulmonary disease spectrum
(Table 4). Furthermore, our results indicate that only a limited
number of combinations show meaningful association with disease
severity. The combination of IL-6 hi with IFN-c hi or IFN-c lo was
the most decisive in determining disease severity. This observation
is in line with the recently described function of IL-6 as part of the
Th2 loop [28]. The other interesting combination which showed
clear cut differences in disease severity was IFN-c hi or IFN-c lo
with IL-10 SNPs. IFN-c hi in the presence of IL-10int showed
association with pulmonary advanced disease while IFN-c lo with
IL-10 lo also showed an association with pulmonary advanced
disease indicating the critical role of IL-10 in reducing collateral
lung tissue damage. Combination of IFN-c hi or IFN-c lo with TNF-
a hi or TNF-a lo SNPs showed only weak associations at best but it
was clear that different combinations were associated with either
less or more severe disease.
The immune response to M. tuberculosis infection is broad-
ranging and complex. M. tuberculosis has evolved many strategies
for circumventing the host’s immune defenses. CD4-activated
IFN-c appears to be essential [5], [46], though not sufficient, for
maintenance of latency [47]. TNF-a plays an important role in
maintaining the integrity of granulomae, and preventing reacti-
vation [13], and IL-10 appears to be important in reducing
collateral damage and determination of severity [22]. In household
contact biomarker studies, early progression to disease has been
associated with alterations in the production of regulatory Th-2
cytokines, such as IL-4 [29], and IL-10 [48], Thus, the balance of
pro inflammatory and suppressive immune responses appears to
be important in controlling protection and or disease severity in
tuberculosis. Our results with cytokine high and low producer
phenotypes are consistent with the biological functions defined for
these cytokines.
In conclusion our study highlights the importance of careful
stratification of patient groups according to disease severity in
association studies. Secondly, single gene association studies of
even the most important player i.e. IFN-c in mycobacterial
immunity may lead to misleading results. Therefore, additional
multi-loci gene interaction studies are warranted in different ethnic
populations to understand the significance of different dominant or
recessive phenotype effects in disease outcome in TB.
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